Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review - PubMed
3 hours ago
- #biologic-therapy
- #cardiovascular-outcomes
- #inflammatory-dermatoses
- Chronic systemic inflammation in inflammatory dermatoses like psoriasis is linked to atherosclerosis and adverse cardiovascular events.
- Biologic therapies targeting pro-inflammatory cytokines may reduce vascular inflammation and cardiovascular risk.
- Systematic review includes studies on TNF-α, IL-12/23, IL-17, IL-23, and IL-4/13 inhibitors in psoriasis, psoriatic arthritis, hidradenitis suppurativa, and atopic dermatitis.
- TNF-α inhibitors show reduced risk of major adverse cardiovascular events (MACE) compared to conventional therapies, despite risks in heart failure patients.
- Mechanistic studies indicate improvements in cardiovascular markers like CRP, endothelial function, and arterial stiffness with TNF-α inhibitors.
- IL-12/23, IL-17, IL-23, and IL-4/13 inhibitors show cardiovascular safety but no consistent MACE reduction.
- Potential safety signal for IL-23 inhibitor risankizumab with higher cerebrovascular event incidence.
- Heterogeneity in study design and limited long-term data affect consistency of results across biologic classes.